Professor
University of Texas MD Anderson
Eugenie S. Kleinerman, M.D. is a Tenured Professor in the Department of Pediatrics and the Department of Cancer Biology at MD Anderson Cancer Center, Houston TX. She holds the Mary V. and John A. Reilly Distinguished Chair and served a Chair of Pediatrics from 2001-2015. Dr. Kleinerman received her BA degree from Washington University in St. Louis and her MD from Duke University. She completed her pediatric residency at the Children’s National Medical Center in Washington, DC, and her fellowship at the National Cancer Institute in Bethesda, MD. Dr. Kleinerman has devoted her career to studying and improving treatments for children with osteosarcoma. She pioneered the use of the immunotherapy Mepact that significantly improved the survival of patients with osteosarcoma. When combined with chemotherapy, Mepact produced a 30% reduction in mortality at 8 years in newly diagnosed patients and was approved by the European Medicine Agency in 2010. She pioneered aerosol administration targeting sarcoma lung metastases, showed that the FAS/FasL pathway plays a critical role in osteosarcoma metastasis, that Fas expression is controlled by the mi-R-17-92 cluster, and is the first to show that EWS-FLI-1 and the Notch signaling pathway control vasculogenesis in Ewing’s sarcoma. Her most recent focus is on developing a dendritic cell vaccine therapy for osteosarcoma lung metastase and using exercise to decrease the cardiotoxic effects of Doxorubicin chemotherapy. She has served on numerous NIH study sections, as well as an FDA Advisory Panel. Dr. Kleinerman has trained more than 50 graduate students. She has a sustained publication record with >225 articles in high impact peer-reviewed journals, as well as 26 Book Chapters. Awards include the Distinguished Medical Alumnus Award from Duke University, MD Anderson's Faculty Achievement Award in Clinical Research, and the Distinguished Alumni Award from Washington University.
